Compare Bristol-Myers Squibb Co (BMY) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Iron Mountain Inc — how do they compare? Bristol-Myers Squibb Co trades at $59.02 (market cap $116.30B), while Iron Mountain Inc trades at $120.63 (market cap $36.49B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.2× Iron Mountain Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | IRM | |
|---|---|---|
Market Cap | $116.30B | $36.49B |
Sector | Health | Real Estate |
52-Week High | $62.37 | $133.06 |
52-Week Low | $42.60 | $78.86 |
Enterprise Value | $152.24B | $55.63B |
Dividend Yield | 4.42% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Iron Mountain (IRM) trades at $122.37, up 0.72% on the day, showing strong momentum with a 30.2% gain over three months. The stock is in a bullish technical trend, supported by recent earnings beats and positive analyst sentiment. Revenue growth accelerated to $6.90 billion in 2025, though net margins remain thin at 3.76%. Recent news highlights its data center strength and a $1.5 billion debt offering to fund expansion.
Outlook is cautiously optimistic with a consensus price target of $138.67 offering 13% upside. Risks include high debt levels (debt-to-asset ratio of 79.04% in 2025) and margin pressure. The stock appeals for its growth exposure and dividend yield, but investors should weigh leverage concerns against operational momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
